Tideglusib is under clinical development by AMO Pharma and currently in Phase III for Myotonic Dystrophy. According to GlobalData, Phase III drugs for Myotonic Dystrophy does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Tideglusib LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tideglusib overview
Tideglusib (AMO-02/NP-12) is under development for the treatment of congenital and juvenile onset myotonic dystrophy, duchenne muscular dystrophy, arrhythmogenic cardiomyopathy (ACM) and autism spectrum disorder. It is administered through the oral route. The drug candidate acts by targeting glycogen synthase kinase 3 beta and RNA ligase. The drug candidate is a disease-modifying thiazolidine derivative. The drug candidate was also under development for the treatment of Alzheimer's disease, fragile X syndrome and progressive supranuclear palsy (PSP).
AMO Pharma overview
AMO Pharma is a biopharmaceutical company that develops novel treatments for serious and debilitating diseases. The company’s product portfolio comprises AMO-01, AMO-02 and AMO-04. Its AMO-01 is an inhibitor of the ras-extracellular signal-regulated kinase pathway (Ras-ERK) that treats Phelan-McDermid syndrome; AMO-02 which is used for the treatment of myotonic dystrophy, CNS, neuromuscular and oncology indications; AMO-04 targets Rett syndrome. The company provides target therapy areas such as central nervous system disorders, neuromuscular and Steinert’s disease. It also has operations in the US and the UK. Amo Pharma is headquartered in London, England, the UK.
For a complete picture of Tideglusib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
